Zolbetuximab-clzb
Zolbetuximab-clzb works by binding to a protein called CLDN18.2, which some cancer cells produce in large amounts. This helps the immune system find and attack the cancer cells. Zolbetuximab-clzb also helps weaken the cancer cell membrane, which can cause cancer cells to die. It is a type of targeted therapy called a monoclonal antibody.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Zolbetuximab-clzb is approved to treat adults with:
- stomach (gastric) cancer or gastroesophageal junction cancer that is HER2 negative, has the CLDN18.2 protein, and has spread. It is used with a fluoropyrimidine and platinum-based chemotherapy as the first treatment.
Zolbetuximab-clzb is also being studied in the treatment of other types of cancer.
More About Zolbetuximab-clzb
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Zolbetuximab-clzb - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Zolbetuximab-clzb - Check for trials from NCI's list of cancer clinical trials now accepting patients.